Quanterix Launches Multiplex Panel To Study Tbi Severity
Quanterix Corp, Lexington, Mass, has launched the Simoa Neurology 4-Plex A assay (N4PA). The Simoa N4PA assay can simultaneously measure four protein biomarkers from either cerebrospinal fluid (CSF) or directly from blood samples for the study of traumatic brain injury (TBI) and other neurodegenerative conditions. The four biomarkers used on the panel include neurofilament light (NF-L), tau, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1).
Recent studies indicate that serum NF-L is a biomarker for mild TBI in amateur boxers and professional hockey players, that plasma tau is related to concussion severity and return-to-play, and that serum GFAP and UCH-L1 can detect mild to moderate TBI.1–3 The TBI endpoints development initiative has also hosted a 2017 consensus conference, where thought leaders have identified NF-L, tau, GFAP, and UCH-L1 as the top four fluid biomarkers of interest for mild TBI assessment.
“The Simoa N4PA panel is an essential research tool for assessing head trauma-induced neural damage, particularly mild cases of TBI, which are the hardest to detect,” says Kevin Hrusovsky, executive chairman and CEO at Quanterix.
Read the rest of the article at clpmag.com
Share this page